RxDoctor Payments Data

Aruna Rao, MD

Internal Medicine · E Brunswick, NJNPI 1508821489

Payments from drug & device makers

$468in general payments, 2019–2025

Across 15 payments — averaging $31.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$137
  • AstraZeneca$128
  • Boston Scientific$76
  • Novo Nordisk$40
  • Exact Sciences$20
  • Acadia Pharmaceuticals Inc$15
  • plus $51 from 4 others

What the payments were for

  • Food & beverage$468100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$468 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$244,915
Medicare patients
122
Services billed
2,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$47,794
JanuviaSitagliptin Phosphate53$32,720
InvokanaCanagliflozin16$20,956
MyrbetriqMirabegron49$18,446
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$10,876
FarxigaDapagliflozin Propanediol21$8,882
JanumetSitagliptin Phos/Metformin Hcl11$6,703
Lacosamide44$6,412
EntrestoSacubitril/Valsartan13$5,741
BrilintaTicagrelor24$5,435
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$5,109
Potassium Chloride101$4,429
Atorvastatin Calcium268$4,313
Celecoxib88$3,745
Arnuity ElliptaFluticasone Furoate12$3,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$14$39,42364 claims
AstraZenecaFarxiga, Brilinta$128$14,31645 claims
NovartisEntresto$11$5,74113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in E Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →